-
Study aim
-
The aim of this study is to assess the effect of adding Dexmedetomidine to Ropivacaine on pain after thoracotomy.
-
Design
-
Double-blind clinical trial, with parallel, randomized groups, phase 3 on 74 patients, randomization using www.Randomizer.org service
-
Settings and conduct
-
Thoracotomy patients in Ahvaz Imam Khomeini Hospital undergo intercostal nerve block. Physician in charge of injection, the patients and the outcome assessors are blinded to the study by using a transparent label coded syringe. only the physician in charge of preparing the syringe is aware of the contents.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria:
Age 18 to 60 years,
American Society of Anesthesiologists physical status Class I, II or III,
Body Mass Index less than 40,
No history of substance or alcohol abuse,
No pregnancy or breastfeeding,
No history of coagulation problems or use of anticoagulants,
Ejection fraction above 30%,
No history of cardiac conduction block (except for first-degree cardiac block and controlled atrial fibrillation),
No acute or chronic hepatitis,
No history of psychiatric illness,
No need for renal supplementation or a history of kidney failure,
Absence of Neuropathy,
Exclusion Criteria:
Hypersensitivity to study medication
-
Intervention groups
-
At the end of thoracotomy, after extubation and hemodynamic stability, the intercostal nerve block is done using a code labeled transparent syringe under ultrasound guidance (M7, MindRay China) by a Pain Fellowship. the intercostal nerve block is done one space above and two spaces below the surgical incision site.
Control Group: 5 cc Ropivacaine (Molteni Farmaceutici, Italy) 0.25% is injected in the three spaces.
Intervention Group: in Addition to Ropivacaine (5cc, 0.25%), Dexmedetomidine (Exir Pharmaceutical Co., Iran), 0.5 mcg/kg is injected, divided between the three spaces.
-
Main outcome variables
-
Post operative Pain